These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 25273866)

  • 1. Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
    da Fonseca LG; Barroso-Sousa R; Bento Ada S; Blanco BP; Valente GL; Pfiffer TE; Hoff PM; Sabbaga J
    Med Oncol; 2014 Nov; 31(11):264. PubMed ID: 25273866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib.
    Zheng YB; Zhao W; Liu B; Lu LG; He X; Huang JW; Li Y; Hu BS
    Asian Pac J Cancer Prev; 2013; 14(9):5527-31. PubMed ID: 24175853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutrophil-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib.
    Wei K; Wang M; Zhang W; Mu H; Song TQ
    Med Oncol; 2014 Jun; 31(6):969. PubMed ID: 24793745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib.
    Hong YM; Yoon KT; Hwang TH; Heo J; Woo HY; Cho M
    Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1250-1255. PubMed ID: 30925530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.
    Bruix J; Cheng AL; Meinhardt G; Nakajima K; De Sanctis Y; Llovet J
    J Hepatol; 2017 Nov; 67(5):999-1008. PubMed ID: 28687477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score.
    Edeline J; Blanc JF; Campillo-Gimenez B; Ma YT; King J; Faluyi O; Mathurin J; Ghazi S; Palmer DH; Meyer T
    Eur J Cancer; 2017 Nov; 86():135-142. PubMed ID: 28987770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma.
    Kim HY; Park JW; Joo J; Kim H; Woo SM; Lee WJ; Kim CM
    J Gastroenterol Hepatol; 2013 Nov; 28(11):1756-61. PubMed ID: 23800278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib.
    Chen D; Zhao P; Li SQ; Xiao WK; Yin XY; Peng BG; Liang LJ
    Eur J Surg Oncol; 2013 Sep; 39(9):974-80. PubMed ID: 23845703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib for the Treatment of Advanced Hepatocellular Cancer - a UK Audit.
    King J; Palmer DH; Johnson P; Ross P; Hubner RA; Sumpter K; Darby S; Braconi C; Iwuji C; Swinson D; Collins P; Patel K; Nobes J; Muazzam I; Blesing C; Kirkwood A; Nash S; Meyer T
    Clin Oncol (R Coll Radiol); 2017 Apr; 29(4):256-262. PubMed ID: 27964898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.
    Wörns MA; Koch S; Niederle IM; Marquardt JU; Nguyen-Tat M; Gamstätter T; Schuchmann M; Schulze-Bergkamen H; Galle PR; Weinmann A
    Dig Liver Dis; 2013 May; 45(5):408-13. PubMed ID: 23182599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
    Lee SH; Song IH; Noh R; Kang HY; Kim SB; Ko SY; Lee ES; Kim SH; Lee BS; Kim AN; Chae HB; Kim HS; Lee TH; Kang YW; Lee JD; Lee HY
    BMC Cancer; 2015 Apr; 15():236. PubMed ID: 25885683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma.
    Di Costanzo GG; Casadei Gardini A; Marisi G; Foschi FG; Scartozzi M; Granata R; Faloppi L; Cascinu S; Silvestris N; Brunetti O; Palmieri VO; Ercolani G; Tortora R
    Target Oncol; 2017 Dec; 12(6):795-803. PubMed ID: 28770532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib.
    Casadei Gardini A; Scarpi E; Faloppi L; Scartozzi M; Silvestris N; Santini D; de Stefano G; Marisi G; Negri FV; Foschi FG; Valgiusti M; Ercolani G; Frassineti GL
    Oncotarget; 2016 Oct; 7(41):67142-67149. PubMed ID: 27613839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma.
    Wada Y; Takami Y; Tateishi M; Ryu T; Mikagi K; Saitsu H
    PLoS One; 2016; 11(1):e0146456. PubMed ID: 26745625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma: a single center experience.
    Imedio ER; Beveridge RD; Urtasun JA; Campos GB; Estellés DL; Esparcia MF; Daroqui JC; Huerta ÁS; Ortiz AG; Salcedo JM
    Med Oncol; 2014 May; 31(5):948. PubMed ID: 24740650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
    Yada M; Masumoto A; Motomura K; Tajiri H; Morita Y; Suzuki H; Senju T; Koyanagi T
    World J Gastroenterol; 2014 Sep; 20(35):12581-7. PubMed ID: 25253961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice.
    Lee IC; Chen YT; Chao Y; Huo TI; Li CP; Su CW; Lin HC; Lee FY; Huang YH
    Medicine (Baltimore); 2015 Apr; 94(14):e688. PubMed ID: 25860213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib.
    Diaz-Beveridge R; Bruixola G; Lorente D; Caballero J; Rodrigo E; Segura Á; Akhoundova D; Giménez A; Aparicio J
    Clin Transl Oncol; 2018 Mar; 20(3):322-329. PubMed ID: 28801777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.
    Inghilesi AL; Gallori D; Antonuzzo L; Forte P; Tomcikova D; Arena U; Colagrande S; Pradella S; Fani B; Gianni E; Boni L; Laffi G; Di Costanzo F; Marra F
    World J Gastroenterol; 2014 Jan; 20(3):786-94. PubMed ID: 24574751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience.
    Abdel-Rahman O; Abdelwahab M; Shaker M; Abdelwahab S; Elbassiony M; Ellithy M
    J Egypt Natl Canc Inst; 2014 Mar; 26(1):9-13. PubMed ID: 24565677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.